Cardioprotective Effects of a Phlorotannin Extract Against Doxorubicin-Induced Cardiotoxicity in a Rat Model

2017 ◽  
Vol 20 (10) ◽  
pp. 944-950 ◽  
Author(s):  
Hyo-Suk Ahn ◽  
Dong-Hyeon Lee ◽  
Tae-Jung Kim ◽  
Hyeon-Cheol Shin ◽  
Hui-Kyung Jeon
2018 ◽  
Vol 25 (3) ◽  
pp. 217
Author(s):  
Jovana Jeremic ◽  
Ivan Srejovic ◽  
Vladimir Zivkovic ◽  
Tamara Nikolic Turnic ◽  
Isidora Milosavljevic ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Elena Piegari ◽  
Anna Cozzolino ◽  
Loreta Pia Ciuffreda ◽  
Donato Cappetta ◽  
Antonella De Angelis ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Hongbo Wang ◽  
Pengfei Yu ◽  
Haitao Gou ◽  
Jianqiao Zhang ◽  
Mei Zhu ◽  
...  

Doxorubicin (DOX) is considered as one of the best antineoplastic agents. However, its clinical use is restricted by its associated cardiotoxicity, which is mediated by the production of reactive oxygen species. In this study, 20(S)-ginsenoside Rh2 (Rh2) was explored whether it had protective effects against DOX-induced cardiotoxicity.In vitrostudy on H9C2 cell line, as well asin vivoinvestigation in one mouse and one rat model of DOX-induced cardiomyopathy, was carried out. The results showed that pretreatment with Rh2 significantly increased the viability of DOX-injured H9C2 cells. In the mouse model, Rh2 could suppress the DOX-induced release of the cardiac enzymes into serum and improved the occurred pathological changes through ameliorating the decreased antioxidant biomolecules and the cumulated lipid peroxidation malondialdehyde in heart tissues. In the rat model, Rh2 could attenuate the change of ECG resulting from DOX administration. Furthermore, Rh2 enhanced the antitumor activity of DOX in A549 cells. Our findings thus demonstrated that Rh2 pretreatment could effectively alleviate heart injury induced by DOX, and Rh2 might act as a novel protective agent in the clinical usefulness of DOX.


2021 ◽  
pp. 33-43
Author(s):  
I MARKOVÁ ◽  
H MALÍNSKÁ ◽  
M HÜTTL ◽  
D MIKLÁNKOVÁ ◽  
O OLIYARNYK ◽  
...  

Hypolipidemic and cardioprotective effects of statins can be associated with the development of myopathies and new-onset type 2 diabetes. These adverse effects may be related to increased oxidative stress. The plant extract silymarin (SM) is known for its antioxidant and anti-inflammatory actions. We tested the hypothesis that the combination of atorvastatin (ATV) with SM could improve therapy efficacy and eliminate some negative effects of statin on hypertriglyceridemia-induced metabolic disorders. Hereditary hypertriglyceridemic rats were fed a standard diet for four weeks without supplementation; supplemented with ATV (5 mg/kg b. wt./day) or a combination of ATV with 1 % micronized SM (ATV+SM). ATV treatment elevated plasma levels of HDL-cholesterol (p<0.01), glucose and insulin and decreased triglycerides (p<0.001). The combination of ATV+SM led to a significant reduction in insulin, an improvement of glucose tolerance, and the hypolipidemic effect was enhanced compared to ATV alone. Furthermore, ATV supplementation increased skeletal muscle triglycerides but its combination with SM decreased triglycerides accumulation in the muscle (p<0.05) and the liver (p<0.01). In the liver, ATV+SM treatment increased the activities of antioxidant enzymes, glutathione and reduced lipid peroxidation (p<0.001). The combined administration of ATV with SM potentiated the hypolipidemic effect, reduced ectopic lipid accumulation, improved glucose metabolism, and increased antioxidant and anti-inflammatory actions. Our results show that SM increased the effectiveness of statin therapy in a hypertriglyceridemic rat model of metabolic syndrome.


2019 ◽  
Vol 168 (1) ◽  
pp. 33-37
Author(s):  
S. A. Kryzhanovskii ◽  
I. B. Tsorin ◽  
V. N. Stolyaruk ◽  
M. B. Vititnova ◽  
E. O. Ionova ◽  
...  

2014 ◽  
Vol 391 (1-2) ◽  
pp. 22-29 ◽  
Author(s):  
Alexandre Luz de Castro ◽  
Angela Vicente Tavares ◽  
Cristina Campos ◽  
Rafael Oliveira Fernandes ◽  
Rafaela Siqueira ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document